IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr

Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22

Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab

This approval reflects Biocon Biologics' compliance with the highest international regulatory standards

RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr

Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23

Atul appoints Rangaswamy Iyer as Independent Director

The appointment is effective from May 01, 2023 for five years

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness

PI Industries announces twin acquisitions into Pharma API & CDMO space

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.

Serum & Biocon Biologics agree to restructure equity investment

Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio

Indica Labs and Lunit enters into alliance for digital pathology AI workflows

Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution

USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013

This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology